This activity is supported by an educational grant from AstraZeneca, Bristol-Myers Squibb, Celgene, Lilly, and Merck.
Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinoma of the Lung
Millie Das, MD
Stanford University and VA Palo Alto
Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP®
Stanford Cancer Center
Following years in which there were only modest gains in treatment options for non–small cell lung cancer, the number of drugs approved in the past 5 years is unprecedented. Recognition of targetable mutations and immunogenicity of lung cancer now impact treatment decisions. This educational activity will provide the advanced practitioner with updates on the latest research, current guidelines in the diagnosis and workup, as well as information on novel treatments and side effect management to ensure the best outcomes for patients with NSCLC.
These CME/CE/CPE accredited activities are jointly provided by